Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

Blood (2015) 126 (23): 27.

https://doi.org/10.1182/blood.V126.23.27.27

Published: 2015

Journal Articles

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Maximilian Merz, MD, Hans-Juergen Salwender, MD, Mathias Haenel, MD, Uta Bertsch, MD, Christina Kunz, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Bärbel Schurich, Markus Munder, MD, Peter Brossart, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja C. Weisel, Jan Duerig, MD, Hartmut Goldschmidt, MD

Blood (2015) 126 (23): 4233.

https://doi.org/10.1182/blood.V126.23.4233.4233

Published: 2015

Journal Articles

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Maximilian Merz, MD, Hans Salwender, MD, Mathias Hänel, MD, Uta Bertsch, MD, Christina Kunz, PhD, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Baerbel Schurich, PhD, Markus Munder, MD, Ingo GH Schmidt-Wolf, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja Weisel, MD, Jan Duerig, MD, Hartmut Goldschmidt, MD

Blood (2014) 124 (21): 3475.

https://doi.org/10.1182/blood.V124.21.3475.3475

Published: 2014

Journal Articles

Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial

Annika Scheffold, MSc, Billy Michael Chelliah Jebaraj, PhD, Eugen Tausch, MD, Sebastian Boettcher, MD, Matthias Ritgen, Donald Bunjes, MD, Matthias Zeis, MD, Michael Stadler, MD, Lutz Uharek, MD, Christof Scheid, MDPhD, Ute Hegenbart, MD, Michael Hallek, MD, Michael Kneba, MD PhD, Norbert Schmitz, MD PhD, Hartmut Doehner, MD, Peter Dreger, MD, Stephan Stilgenbauer, MD

Blood (2014) 124 (21): 1951.

https://doi.org/10.1182/blood.V124.21.1951.1951

Published: 2014

Journal Articles

Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG

Christof Scheid, MDPhD, Thomas Hielscher, Uta Bertsch, MD, Christina Kunz, PhD, Hans Salwender, MD, Mathias Haenel, Maximilian Merz, Elias Karl Mai, MD, Dirk Hose, MD PhD, Baerbel Schurich, PhD, Markus Munder, MD, Ingo Schmidt-Wolf, MD, Christian Gerecke, MD, Walter Lindemann, MD, Matthias Zeis, MD, Katja Weisel, MD, Jan Duerig, MD, Anna Jauch, PhD, Hartmut Goldschmidt, MD

Blood (2014) 124 (21): 4777.

https://doi.org/10.1182/blood.V124.21.4777.4777

Published: 2014

Journal Articles

Flamsa Reduced-Intensity Conditioning Regimen in AML Patients – Role of Re-Induction and Disease State Prior to Transplant

Udo Holtick, MDPhD, Alexander Shimabukuro-Vornhagen, MD, Geothy Chakupurakal, MBBS, MRCPath, PhD, Sebastian Theurich, MD, Silke Leitzke, Dominik Wolf, MD, Michael Hallek, MD, Michael S. von Bergwelt-Baildon, MD PhD, Christof Scheid, MDPhD, Jens Chemnitz, MD

Blood (2014) 124 (21): 3904.

https://doi.org/10.1182/blood.V124.21.3904.3904

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial

Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG

Flamsa Reduced-Intensity Conditioning Regimen in AML Patients – Role of Re-Induction and Disease State Prior to Transplant

Email alerts

ASH Publications

American Society of Hematology

Update search

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial

Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG

Flamsa Reduced-Intensity Conditioning Regimen in AML Patients – Role of Re-Induction and Disease State Prior to Transplant

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only